Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Washington, District of Columbia 20037


Purpose:

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Interferon alfa may interfere with the growth of the cancer cells. Combining interferon alfa with chemotherapy may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of fluorouracil plus interferon alfa in treating patients who have advanced metastatic carcinoid tumors.


Study summary:

OBJECTIVES: - Determine the objective response rate and duration of remission in patients with advanced metastatic carcinoid tumors treated with fluorouracil and interferon alfa-2b. - Determine the symptomatic response in patients treated with this regimen. - Determine the toxicity of this regimen in these patients. - Determine the quality of life of patients treated with this regimen. - Determine the survival characteristics of patients treated with this regimen. OUTLINE: Patients receive fluorouracil IV continuously for 10 weeks and interferon alfa subcutaneously 3 times a week for 12 weeks. Treatment continues every 12 weeks in the absence of disease progression or unacceptable toxicity. Quality of life is assessed at baseline and at weeks 1, 7, and 11 of each course. Patients are followed every 3 months. PROJECTED ACCRUAL: A total of 50 patients will be accrued for this study.


Criteria:

DISEASE CHARACTERISTICS: - Histologically proven carcinoid tumor with radiologically confirmed metastatic disease - Recurrence after surgery or radiotherapy allowed - Must meet at least 1 of the following conditions: - Symptomatic carcinoid syndrome not controlled - Other systemic symptoms (e.g., weight loss, anorexia) - 24 hour urinary 5-hydroxyindole acetic acid (5-HIAA) 100 mg or greater - Bone metastases - Carcinoid heart disease - Carcinoid asthma - Measurable disease or 24-hour urinary 5-HIAA 50 mg or greater required - No known brain metastases PATIENT CHARACTERISTICS: Age: - 18 and over Performance status: - Zubrod 0-2 Hematopoietic: - Granulocyte count at least 1,500/mm^3 - Platelet count at least 100,000/mm^3 Hepatic: - Bilirubin no greater than 3.0 mg/dL Renal: - Creatinine no greater than 2.0 mg/dL Cardiovascular: - See Disease Characteristics Pulmonary: - See Disease Characteristics Other: - No concurrent infection (no fever for at least 3 days prior to treatment unless fever due to tumor) - No significant medical or psychiatric illness that would preclude study or informed consent - No other malignancy within the past 5 years except basal cell or squamous cell skin cancer or curatively treated stage I carcinoma of the cervix - Not pregnant - Fertile patients must use effective contraception PRIOR CONCURRENT THERAPY: Biologic therapy: - No prior interferon therapy Chemotherapy: - No other concurrent chemotherapy Endocrine therapy: - Prior endocrine therapy allowed - Concurrent octreotide allowed Radiotherapy: - See Disease Characteristics - At least 4 weeks since prior radiotherapy - No concurrent radiotherapy Surgery: - See Disease Characteristics - Prior surgery allowed Other: - No prior fluorinated pyrimidine


NCT ID:

NCT00002470


Primary Contact:

Study Chair
James D. Ahlgren, MD
George Washington University


Backup Contact:

N/A


Location Contact:

Washington, District of Columbia 20037
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: October 23, 2017

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.